Europe

NHS England releases statement after the Scottish government agrees to a deal with Vertex Pharma to provide around 400 people with cystic fibrosis access to Orkambi and Symkevi.

Over the last twenty years or so, the UK's NHS has borrowed money over 100 times via private (i.e. non-government) loans - to be repaid with interest.

The move comes one month after the Scottish Medicines Consortium had recommended the National Health Service in Scotland should not cover the Orkambi and Symkevi medicines.

Europe’s biotechs currently receive only 20 percent of the funding their US counterparts do.

A five year pricing agreement to supply NHS Scotland with medicines to benefit patients living with cystic fibrosis in Scotland has been secured following discussions between Vertex Pharmaceuticals and the Scottish Government.

The UK government on Wednesday published a previously sensitive document explaining how a no-deal Brexit beginning on 31 October could strain trade across the English Channel for up to six months.

The number of UK-born people living in the EU - workers and their dependants, pensioners, students and others - is estimated at 1.3 million.

Novartis’ Kymriah (tisagenlecleucel) has received routine reimbursement for all eligible UK patients on the NHS, following appraisal from the Scottish Medicines Consortium.

Britain is facing a drugs crisis, as many people rely on highly addictive prescription drugs.

The Scottish Medicines Consortium (SMC) has approved Dovato (dolutegravir/lamivudine) for use on the NHS.

More and more Britons are being prescribed potentially addictive medicines including sleeping pills, opioids and other painkillers, raising the risk of a drug crisis like the one in the United States.

An overview of terminology and process.

Universal health coverage depends on affordable medicines. But pushing down prices without also investing in quality assurance will increase the sale of substandard and falsified drugs.

Drug company Novartis agreed a discount for the NHS on the £613,410 price.

The MHRA has published more than 30 documents providing guidance and information on the regulation of medicines and medical devices if there is a no-deal Brexit.